Ted Mullin Fund Minneapolis

Ted Mullin Fund Minneapolis Money raised acts as seed funding for Comer Children's Hospital's pediatric sarcoma research program.

Since 2006, Mullin family and friends have raised almost $800,000 for the Ted Mullin Fund, allowing The University of Chicago Medicine (UCM) to launch its pediatric sarcoma research program. The Ted Mullin Fund has supported research into novel chemotherapy/biology agents for sarcomas, new ways to administer chemotherapy in this disease, techniques to visualize more accurately the tumor response i

n the patient, novel genomics strategies to identify high-risk sarcoma patients, molecular techniques to personalize therapy to maximize benefit while reducing treatment-related toxicity, and treatments for metastatic or resistant disease that use the patient's own immune system to attack residual tumors. Each summer, UCM hosts Ted Mullin Fund Scholars in pediatric cancer laboratories, giving collegiate Ted Mullin "Hour of Power" participants an opportunity to advance their interest in science and cancer biology. UCM is celebrating the first anniversary of the Adolescent and Young Adult Oncology Program that initially focused on leukemia and sarcoma, and now has added lymphoma to the program. Future plans include, in collaboration with other national programs, the establishment of a consortium to facilitate more rapid development and availability of new molecular and biologic therapeutics.

Address

Minneapolis, MN

Website

Alerts

Be the first to know and let us send you an email when Ted Mullin Fund Minneapolis posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Ted Mullin Fund Minneapolis:

Shortcuts

Share

Category

Our Story

Since 2006, Mullin family and friends have raised over one million dollars for the Ted Mullin Fund, allowing The University of Chicago Medicine (UCM) to launch its pediatric sarcoma research program. Money raised acts as seed funding for Comer Children's Hospital's pediatric sarcoma research program. The Ted Mullin Fund has supported research into novel chemotherapy/biology agents for sarcomas, new ways to administer chemotherapy in this disease, techniques to visualize more accurately the tumor response in the patient, novel genomics strategies to identify high-risk sarcoma patients, molecular techniques to personalize therapy to maximize benefit while reducing treatment-related toxicity, and treatments for metastatic or resistant disease that use the patient's own immune system to attack residual tumors. Each summer, UCM hosts Ted Mullin Fund Scholars in pediatric cancer laboratories, giving collegiate Ted Mullin "Hour of Power" participants an opportunity to advance their interest in science and cancer biology. UCM is celebrating the first anniversary of the Adolescent and Young Adult Oncology Program that initially focused on leukemia and sarcoma, and now has added lymphoma to the program. Future plans include, in collaboration with other national programs, the establishment of a consortium to facilitate more rapid development and availability of new molecular and biologic therapeutics.